CD4 and neoplasm: Compared to chemotherapy alone, neoadjuvant camrelizumab combined with chemotherapy influenced the densities of CD3+, CD4+ and CD8+ T cells, M1 tumor-associated macrophages, CD20+ B cells and T cells expressing PD1 in the tumor microenvironment.